This content is machine translated ACC 2018 Success story of PCSK9 inhibition continues For the first time after the highly acclaimed FOURIER trial, a PCSK9 inhibitor now also shows a mortality benefit in secondary prevention. The product in question is alirocumab. Experts are…
View Post 6 min This content is machine translated ACC Congress in Chicago Cholesterol management under the microscope Two studies in the field of lipid therapy caused a stir at the ACC Congress in Chicago. HOPE-3 presented a pragmatic approach to primary prevention for discussion. The study showed…
